Abstract
We investigated the stock price behavior of public pharmaceutical and biotechnology companies upon approval of a drug by the Food and Drug Administration (FDA). Using event study methodology, we examine the reaction caused by the approval, seperating it from the asset price movements caused by other factors such as market and industry effects. The results are then used to validate the model developed in this article as an alternative to the explanations given by Sharma and Lacey (2004). The results of this study support the Efficient Market Hypothesis, i.e. that the market reacts to the new information quickly and clearly.
JEL Codes
G14, M13
Keywords
FDA, Pharmaceuticals, Efficient Markets Hypothesis, EMH
Recommended Citation
Sturm, Andreas; Dowling, Michael J.; and Röder, Klaus
(2007)
"FDA Drug Approvals: Time Is Money!,"
Journal of Entrepreneurial Finance and Business Ventures:
Vol. 12:
Iss.
2, pp. 23-54.
DOI: https://doi.org/10.57229/2373-1761.1026
Available at:
https://digitalcommons.pepperdine.edu/jef/vol12/iss2/3
